Effects of (-)-epigallocatechin-3-gallate on cyclooxygenase 2 and matrix metalloproteinase 3, 9,13 expression induced by IL-1ß in rat meniscal fibrochondrocytes

Journal of Food and Drug Analysis

Volumn 17, Issue 6, 2009, Pages 459-466

  Huang, Hsiu Hui ^a,b   Tsao, Tang Yi ^a   Lee, Herng Sheng ^b  

^a TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Cyclooxygenase 2; Epigallocatechin 3 gallate; Fibrochondrocyte; IL 1 ; Matrix metalloproteinase; Meniscus

Indexed keywords

COLLAGENASE 3; CYCLOOXYGENASE 2; EPIGALLOCATECHIN GALLATE; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 1BETA; STROMELYSIN;

ANIMAL CELL; ARTICLE; CARTILAGE CELL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; IMMUNOCYTOCHEMISTRY; KNEE MENISCUS; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

RATTUS;

EID: 77949581387     PISSN: 10219498     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Towle, C. A., Hung, H. H., Bonassar, L. J., Treadwell, B. V. and Mangham, D. C. 1997. Detection of interleukin-1 in the cartilage of patients with osteoarthritis: A possible autocrine/paracrine role in pathogenesis. Osteoarthr. Cartil. 5: 293-300.
2. Messner, K. and Gao, J. 1998. The menisci of the knee joint. Anatomical and functional characteristics, and a rationale for clinical treatment. J. Anat. 193: 161-178.
3. Lewandrowski, K. U., Muller, J. and Schollmeier, G. 1997. Concomitant meniscal and articular cartilage lesions in the femorotibial joint. Am. J. Sports Med. 25: 486-494.
4. Smith, M. D., Triantafillou, S., Parker, A., Youssef, P. P. and Coleman, M. 1997. Synovial membrane inflammation and cytokine production in patients with early Osteoarthritis. J. Rheumatol. 24: 365-371.
5. Moos, V., Fickert, S., Müller, B., Weber, U. and Sieper, J. 1999. Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. J. Rheumatol. 26: 870-879.
6. Melchiorri, C., Meliconi, R., Frizziero, L., Silvestri, T., Pulsatelli, L., Mazzetti, I., Borzi, R. M., Uquccion, M. and Facchini, A. 1998. Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum. 41: 2165-2174.
7. Hardy, M. M., Seibert, K., Manning, P. T., Currie, M. G., Woerner, B. M., Edwards, D., Koki, A. and Tripp, C. S. 2002. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis expiants. Arthritis Rheum. 46: 1789-1803.
8. Vu, T. H. and Werb, Z. 2000. Matrix metalloproteinases: Effectors of development and normal physiology. Genes Dev. 14: 2123-2133.
9. Egeblad, M. and Werb, Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2: 161-174.
10. Skiles, J. W., Gonnella, N. C. and Jeng, A. Y. 2004. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr. Med. Chem. 11: 2911-2977.
11. Takaishi, H., Kimura, T., Dalai, S., Okada, Y. and D'Armiento, J. 2008. Joint diseases and matrix metalloproteinases: A role for MMP-13. Curr. Pharm. Biotechnol. 9: 47-54.
12. Mehraban, F., Lark, M. W., Ahmed, F. N., Xu, F. and Moskowitz, R. W. 1998. Increased secretion and activity of matrix metalloproteinase-3 in synovial tissues and chondrocytes from experimental osteoarthritis. Osteoarthr. Cartil. 6: 286-294.
13. Takahashi, K., Goomer, R. S., Harwood, F., Kubo, T., Hirasawa, Y. and Amiel, D. 1999. The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-lbeta (IL-lbeta), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthr. Cartil. 7: 182-190.
14. Xue, M., March, L., Sambrook, P. N. and Jackson, C. J. 2007. Differential regulation of matrix metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C relevance to inflammation in rheumatoid arthritis. Arthritis Rheum. 56: 2864-2874.
15. Johnson, A. R., Pavlovsky, A. G., Ortwine, D. F., Prior, F., Man, C. F., Bornemeier, D. A., Banotai, C. A., Mueller, W. T., McConnell, P., Yan, C., Baragi, V., Lesch, C., Roark, W. H., Wilson, M., Datta, K., Guzman, R., Han, H. K. and Dyer, R. D. 2007. Discovery and characterization of A novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J. Biol. Chem. 282: 27781-27791.
16. Tu, G., Xu, W., Huang, H. and Li, S. 2008. Progress in the development of matrix metalloproteinase inhibitors. Curr. Med. Chem. 15: 1388-1395.
17. Janusz, M. J., Bendele, A. M., Brown, K. K., Taiwo, Y. O., Hsieh, L. and Heitmeyer, S. A. 2002. Induction of osteoarthritis in the rat by surgical tear of the meniscus: Inhibition of joint damage by a matrix metalloproteinase inhibitor. Osteoarthr. Cartil. 10: 785-791.
18. Katiyar, S. K., Challa, A., McCormick, T. S., Cooper, K. D. and Mukhtar, H. 1999. Prevention of UVB-induced immunosuppression in mice by the green tea polyphenol (-)-epigallocatechin-3-gallate may be associated with alterations in IL-10 and IL-12 production. Carcinogenesis 20: 2117-2124.
19. Devika, P. T. and Stanely Mainzen Prince, P. 2008. Protective Effect of (-)-Epigallocatechin-Gallate (EGCG) on lipid peroxide metabolism in isoproterenol induced myocardial infarction in male Wistar rats: A histopathological study. Biomed. Pharmacother. 62: 701-708.
20. Yang, F., Oz, H. S., Barve, S., de Villiers, W. J., McClain, C. J. and Varilek, G. W. 2001. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. MoI. Pharmacol. 60: 528-533.
21. Albrecht, D. S., Clubbs, E. A., Ferruzzi, M. and Bomser, J. A. 2008. Epigallocatechin-3-gallate (EGCG) inhibits PC-3 prostate cancer cell proliferation via MEK-independent ERK1/2 activation. Chem. Biol. Interact. 171: 89-95.
22. Tang, Y., Zhao, D. Y., Elliott, S., Zhao, W., Curiel, T. J., Beckman, B. S. and Burow, M. E. 2007. Epigallocatechin-3-gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression. Int. J. Oncol. 31: 705-711.
23. Ahmed, S., Rahman, A., Hasnain, A., Lalonde, M., Goldberg, V. M. and Haqqi, T. M. 2002. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1β-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic Biol Med. 33: 1097-1105.
24. Morinobu, A., Bio, W., Tanaka, S., Horiuchi, M., Jun, L., Tsuji, G., Sakai, Y., Kurosaka, M. and Kumagai, S. 2008. (-)-Epigallocatechin-3-gallate suppresses osteoclast differentiation and ameliorates experimental arthritis in mice. Arthritis Rheum. 58: 2012-2018.
25. Andriamanalijaona, R., Kypriotou, M., Bauge, C., Renard, E., Legendre, F., Raoudi, M., Boumediene, K., Gatto, H., Monginoux, P. and Pujol, J. P. 2005. Comparative effects of 2 antioxidants, selenomethionine and epigallocatechin- gallate, on catabolic and anabolic gene expression of articular chondrocytes. J. Rheumatol. 32: 1958-1967.
26. Lee, H. S., Lee, C. H., Tsai, H. C. and Salter, D. M. 2009. Inhibition of cyclooxygenase 2 expression by diallyl sulfide on joint inflammation induced by urate crystal and IL-lbeta. Osteoarthr. Cartil. 17: 91-99.
27. Su, S. L., Tsai, C. D., Lee, C. H., Salter, D. M. and Lee, H. S. 2005. Expression and regulation of toll-like receptor 2 by IL-lbeta and fibronectin fragments in human articular chondrocytes. Osteoarthr. Cartil. 13: 879-886.
28. Ahmed, S., Pakozdi, A. and Koch, A. E. 2006. Regulation of interleukin-lbeta-induced chemokine production and matrix metalloproteinase 2 activation by epigallocatechin-3-gallate in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 54: 2393-2401.
29. Deschner, J., Rath-Deschner, B. and Aqarwal, S. 2006. Regulation of matrix metalloproteinase expression by dynamic tensile strain in rat fibrochondrocytes. Osteoarthr. Cartil. 14: 264-272.
30. 2 modulates cartilage proteoglycan degradation in human osteoarthritis expiants. Arthritis Rheum. 46: 1789-1803.
31. Duffy, M. J., Maquire, T. M., Hill, A., McDermott, E. and O'Hiqqins, N. 2000. Metalloproteinases: Role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2: 252-257.
32. Keleq, S., Büchler, P., Ludwiq, R., Büchler, M. W. and Friess, H. 2003. Invasion and metastasis in pancreatic cancer. MoI. Cancer 22; 2: 14.
33. Kim, M., Murakami, A., Kawabata, K. and Ohigashi, H. 2005. (-)-Epigallocatechin-3-gallate promotes promatrix metalloproteinase-7 production via activation of the JNK1/2 pathway in HT-29 human colorectal cancer cells. Carcinogenesis 26: 1553-1562.
34. Hazgui, S., Bonnomet, A., Nawrocki-Raby, B., Milliot, M., Terryn, C., Cutrona, J., Polette, M., Birebaut, P. and Zahm, J. M. 2008. Epigallocatechin-3-gallate (EGCG) inhibits the migratory behavior of tumor bronchial epithelial cells. Respir. Res. 9: 33.
35. Ho, Y. C., Yang, S. F., Peng, C. Y., Chou, M. Y. and Chang, Y. C. 2007. Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix metalloproteinases and urokinase-plasminogen activator. J. Oral Pathol. Med. 36: 588-593.
36. Vayalil, P. K. and Katiyar, S. K. 2004. Treatment of epigallocatechin-3- gallate inhibits matrix metalloproteinases-2 and -9 via inhibition of activation of mitogen-activated protein kinases, c-jun and NF-kappaB in human prostate carcinoma DU-145 cells. Prostate 59: 33-42.
37. Park, J. W., Jang, Y. H., Kim, J. M., Lee, H., Park, W. K., Lim, M. B., Chu, Y. K., Lo, H. E. and Lee, S. R. 2009. Green tea polyphenol (-)-epigallocatechin gallate reduces neuronal cell damage and up-regulation of MMP-9 activity in hippocampal CA1 and CA2 areas following transient global cerebral ischemia. J. Neurosci. Res. 87: 567-575.
38. Bae, J. Y., Choi, J. S., Choi, Y. J., Shin, S. Y., Kang, S. W., Han, S. J. and Kang, Y. H. 2008. (-)Epigallocatechin gallate hampers collagen destruction and collagenase activation in ultraviolet-B-irradiated human dermal fibroblasts: Involvement of mitogen-activated protein kinase. Food Chem. Toxicol. 46: 1298-1307.
39. Lee, J. H., Chung, J. H. and Cho, K. H. 2005. The effects of epigallocatechin-3-gallate on extracellular matrix metabolism. J. Dermatol. Sci. 40: 195-204.
40. Corps, A. N., Curry, V. A., Buttle, D. J., Hazleman, B. L. and Riley, G. P. 2004. Inhibition of interleukin-lbeta stimulated collagenase and stromelysin expression in human tendon fibroblasts by epigallocatechin gallate ester. Matrix Biol. 23: 163-169.
41. Zhen, M. C., Wang, O., Huang, X. H., Cao, L. O., Chen, X. L., Sun, K., Liu, Y. J., Li, W. and Zhang, L. J. 2007. Green tea polyphenol epigallocatechin-3-gallate inhibits oxidative damage and preventive effects on carbon tetrachloride-induced hepatic fibrosis. J. Nutr. Biochem. 18: 795-805.
42. Zhen, M. C., Huang, X. H., Wang, O., Sun, K., Liu, Y. J., Li, W., Zhang, L. J., Cao, L. O. and Chen, X. L. 2006. Green tea polyphenol epigallocatechin-3-gallate suppresses rat hepatic stellate cell invasion by inhibition of MMP-2 expression and its activation. Acta Pharmacol. Sin. 27: 1600-1607.
43. Yun, H. J., Yoo, W. H., Han, M. K., Lee, Y. R., Kim, J. S. and Lee, S. I. 2008. Epigallocatechin-3-gallate suppresses TNF-alpha -induced production of MMP-1 and -3 in rheumatoid arthritis synovial fibroblasts. Rheumatol. Int. 29: 23-29.
44. Ahmed, S., Wang, N., Lalonde, M., Goldberg, V. M. and Haqqi, T. M. 2004. Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1 beta-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. J. Pharmacol. Exp. Ther. 308: 767-773.
45. McNulty, A. L., Weinberg, J. B., Guilak, F. 2009. Inhibition of matrix metalloproteinases enhances in vitro repair of the meniscus. Clin. Orthop. Relat. Res. 467: 1557-1567.